<p>In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market. </p>

In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.

<p>In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&amp;A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market. </p>

Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

Perspectives from the cutting edge of biotech and pharma.

The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.

Lead today. Define tomorrow.

Business

News

Investing

Business News

Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.

Share Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

Sign up to save your podcasts

Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

More shows like Pathfinders in Biopharma

The Bill Simmons Podcast

RBC's Markets in Motion

Industries in Motion

Powering Sustainable Ideas

The Rest Is Politics

Macro Minutes

Strategic Alternatives

The Rest Is Politics: US